Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study

Background Patient-reported outcomes are increasingly used in the management of patients with multiple sclerosis to understand the patient's perspective of disease and treatment. These measures provide insights into important factors including treatment satisfaction, physical and psychological...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Multiple sclerosis journal - experimental, translational and clinical Ročník 8; číslo 4; s. 20552173221135888
Hlavní autoři: Wray, Sibyl, Jacques, Francois, Miller, Tamara A, Nicholas, Jacqueline A, Arroyo, Rafael, Travis, Lori, Khatri, Bhupendra, Chirieac, Magdalena, Gandhi, Roopali, Roesch, Nora, Rodrigues, Amelie, Melas-Melt, Lydie, Rawlings, Andreea M, Hunter, Samuel F
Médium: Journal Article
Jazyk:angličtina
Vydáno: London, England SAGE Publications 01.10.2022
Sage Publications Ltd
Témata:
Monoclonal antibodies
Multiple sclerosis
Original
Patients
disease-modifying therapies
Alemtuzumab
quality of life
multiple sclerosis
ISSN:2055-2173, 2055-2173
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Background Patient-reported outcomes are increasingly used in the management of patients with multiple sclerosis to understand the patient's perspective of disease and treatment. These measures provide insights into important factors including treatment satisfaction, physical and psychological function, and quality of life. Objective To present results from the real-world PRO-ACT study in patients with multiple sclerosis who switched to alemtuzumab from another disease-modifying therapy. Methods This 24-month, prospective, multicenter, observational study had a primary endpoint of change in overall satisfaction, measured using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4. Secondary endpoints included the Multiple Sclerosis Impact Scale-29 (MSIS-29), Modified Fatigue Impact Scale-5 (MFIS-5), and the Patient-Determined Disease Steps (PDDS). Safety was monitored with adverse events (AEs). Results Of 199 enrolled patients, improvements were observed in mean TSQM scores for overall satisfaction (baseline, 50.3; year 2, + 13.2; p < 0.0001), effectiveness (49.3 and + 12.2; p < 0.0001), and side effects (77.6 and + 4.5; p = 0.04). Improvements were also observed in MSIS-29 physical (52.4 and −6.0; p < 0.0001), MSIS-29 psychological (53.4 and −7.0; p = 0.0003), and MFIS-5 (12.8 and −1.7; p < 0.0001). Most (95.0%) patients experienced ≥ 1 AE (88.4% mild, 67.8% moderate). Conclusions The primary endpoint was met; the safety of alemtuzumab was consistent with pivotal studies.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2055-2173
2055-2173
DOI:10.1177/20552173221135888